- $2.30bn
- $2.90bn
- $14.75m
Annual cashflow statement for Immunitybio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -224 | -350 | -417 | -584 | -414 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 26.3 | 80.3 | 69.6 | 195 | 24.3 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 16.4 | -19.1 | -8 | 3.98 | -19.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -172 | -274 | -338 | -367 | -391 |
| Capital Expenditures | -1.67 | -33.6 | -99.4 | -30.6 | -6.89 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -18.1 | -51.3 | 127 | 0.114 | -5.36 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -19.8 | -84.9 | 27.3 | -30.5 | -12.2 |
| Financing Cash Flow Items | 0 | 1.02 | -0.339 | 0 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 151 | 505 | 234 | 558 | 282 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -40.9 | 146 | -76.3 | 161 | -122 |